39 related articles for article (PubMed ID: 35872068)
1. KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis.
Rabara D; Tran TH; Dharmaiah S; Stephens RM; McCormick F; Simanshu DK; Holderfield M
Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22122-22131. PubMed ID: 31611389
[No Abstract] [Full Text] [Related]
2. The energetic and allosteric landscape for KRAS inhibition.
Weng C; Faure AJ; Escobedo A; Lehner B
Nature; 2024 Feb; 626(7999):643-652. PubMed ID: 38109937
[TBL] [Abstract][Full Text] [Related]
3. Synergy and anti-cooperativity in allostery: Molecular dynamics study of WT and oncogenic KRAS-RGL1.
Hacisuleyman A; Erman B
Proteins; 2024 May; 92(5):665-678. PubMed ID: 38153169
[TBL] [Abstract][Full Text] [Related]
4. Normal Mode Analysis of KRas4B Reveals Partner Specific Dynamics.
Eren M; Tuncbag N; Jang H; Nussinov R; Gursoy A; Keskin O
J Phys Chem B; 2021 May; 125(20):5210-5221. PubMed ID: 33978412
[TBL] [Abstract][Full Text] [Related]
5. SPRED proteins and their roles in signal transduction, development, and malignancy.
Lorenzo C; McCormick F
Genes Dev; 2020 Nov; 34(21-22):1410-1421. PubMed ID: 33872193
[TBL] [Abstract][Full Text] [Related]
6. Mutations influence the conformational dynamics of the GDP/KRAS complex.
Shen C; Yin J; Wang M; Yu Z; Xu X; Zhou Z; Hu Y; Xia C; Hu G
J Biomol Struct Dyn; 2024 Mar; ():1-14. PubMed ID: 38529923
[TBL] [Abstract][Full Text] [Related]
7. RAS MAPK inhibitors deregulation in leukemia.
Pasmant E; Vidaud D; Ballerini P
Oncoscience; 2015; 2(12):930-1. PubMed ID: 26909356
[No Abstract] [Full Text] [Related]
8. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.
Bahar ME; Kim HJ; Kim DR
Signal Transduct Target Ther; 2023 Dec; 8(1):455. PubMed ID: 38105263
[TBL] [Abstract][Full Text] [Related]
9. Decoding the deactivation mechanism of R192W mutation of ZAP-70 using molecular dynamics simulations and binding free energy calculations.
Zhang X; Liang W; Zheng G; Li B
J Mol Model; 2023 Nov; 29(12):371. PubMed ID: 37953318
[TBL] [Abstract][Full Text] [Related]
10. Decoding the Conformational Selective Mechanism of FGFR Isoforms: A Comparative Molecular Dynamics Simulation.
Zhang M; Yasen M; Lu S; Ma DN; Chai Z
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985681
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic insights into the role of calcium in the allosteric regulation of the calmodulin-regulated death-associated protein kinase.
Li X; Li B; Li J; Yang M; Bai Y; Chen K; Chen Z; Mao N
Front Mol Biosci; 2022; 9():1104942. PubMed ID: 36601586
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic Insights into the Protection Effect of Argonaute-RNA Complex on the HCV Genome.
Zhuang H; Ji D; Fan J; Li M; Tao R; Du K; Lu S; Chai Z; Fan X
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358979
[TBL] [Abstract][Full Text] [Related]
13. Computational Dissection of the Role of Trp305 in the Regulation of the Death-Associated Protein Kinase-Calmodulin Interaction.
Zhu YP; Gao XY; Xu GH; Qin ZF; Ju HX; Li DC; Ma DN
Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291604
[TBL] [Abstract][Full Text] [Related]
14. Computer-Aided Drug Design Boosts RAS Inhibitor Discovery.
Wang G; Bai Y; Cui J; Zong Z; Gao Y; Zheng Z
Molecules; 2022 Sep; 27(17):. PubMed ID: 36080477
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic Insights into the Long-range Allosteric Regulation of KRAS Via Neurofibromatosis Type 1 (NF1) Scaffold Upon SPRED1 Loading.
Li M; Wang Y; Fan J; Zhuang H; Liu Y; Ji D; Lu S
J Mol Biol; 2022 Sep; 434(17):167730. PubMed ID: 35872068
[TBL] [Abstract][Full Text] [Related]
16. Structural Insights into the SPRED1-Neurofibromin-KRAS Complex and Disruption of SPRED1-Neurofibromin Interaction by Oncogenic EGFR.
Yan W; Markegard E; Dharmaiah S; Urisman A; Drew M; Esposito D; Scheffzek K; Nissley DV; McCormick F; Simanshu DK
Cell Rep; 2020 Jul; 32(3):107909. PubMed ID: 32697994
[TBL] [Abstract][Full Text] [Related]
17. Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1.
Hirata Y; Brems H; Suzuki M; Kanamori M; Okada M; Morita R; Llano-Rivas I; Ose T; Messiaen L; Legius E; Yoshimura A
J Biol Chem; 2016 Feb; 291(7):3124-34. PubMed ID: 26635368
[TBL] [Abstract][Full Text] [Related]
18. Pathogenic Mutations Associated with Legius Syndrome Modify the Spred1 Surface and Are Involved in Direct Binding to the Ras Inactivator Neurofibromin.
Führer S; Tollinger M; Dunzendorfer-Matt T
J Mol Biol; 2019 Sep; 431(19):3889-3899. PubMed ID: 31401120
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
